Table 2.
Drug adherence characteristics
| Sample size n | 77 |
|---|---|
| Aripiprazole dose | |
| 2 mg | 7 (9%) |
| 5 mg | 8 (10%) |
| 10 mg | 23 (30%) |
| 15 mg | 14 (18%) |
| 20 mg | 10 (13%) |
| 30 mg | 15 (20%) |
| Number of concomitant medications | |
| 1 | 9 (12%) |
| 2 | 9 (12%) |
| 3 | 15 (30%) |
| 4 | 11 (15%) |
| 5 | 9 (12%) |
| 6 | 4 (5%) |
| 7 | 8 (11%) |
| 8 | 3 (4%) |
| 9 | 5 (7%) |
| >10 | 2 (3%) |
| Missing data | 2 |
| Observed ingestion duration, days, median (Range, IQR) | 53 (6–64, 20) |
| Observed ingestion percent %, median (Range, IQR) | 75.9% (18.2–98.3%, 32.9%) |
| Observed fraction of excess dosing events (%), median (Range, IQR) | 0% (0 −14.3%, 3.0%) |